Literature DB >> 19268041

Sleep disorders and daytime sleepiness in Parkinson's disease.

Renee Monderer1, Michael Thorpy.   

Abstract

Patients with Parkinson's disease commonly have sleep disturbances that significantly alter quality of life but are often underrecognized. Awareness of the importance of these sleep disorders has been growing, and more research is being conducted. Patients with Parkinson's disease have difficulties that not only include falling asleep and staying asleep but also include excessive daytime sleepiness and abnormal events during sleep. These sleep disturbances are often multifactorial in nature, resulting from degeneration of the cortical sleep centers to effects of medications taken to treat the motor symptoms associated with Parkinson's disease. A thorough evaluation should be performed to assess for the presence of sleep disturbances and daytime sleepiness. Many therapeutic strategies can be used to treat sleepiness and sleep disturbances in Parkinson's disease to improve the patient's overall health, psychological well-being, and quality of life.

Entities:  

Mesh:

Year:  2009        PMID: 19268041     DOI: 10.1007/s11910-009-0026-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  80 in total

Review 1.  Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function.

Authors:  Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Neuropharmacol       Date:  2002 Jul-Aug       Impact factor: 1.592

2.  Correlates of excessive daytime sleepiness in Parkinson's disease.

Authors:  Jacob Wegelin; Patrick McNamara; Raymon Durso; Ariel Brown; Deirdre McLaren
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

3.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

4.  Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

Authors:  Charles H Adler; John N Caviness; Joseph G Hentz; Marlene Lind; Judy Tiede
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

5.  Preprohypocretin polymorphisms in Parkinson disease patients reporting "sleep attacks".

Authors:  Ida Rissling; Yvonne Körner; Frank Geller; Karin Stiasny-Kolster; Wolfgang H Oertel; J Carsten Möller
Journal:  Sleep       Date:  2005-07       Impact factor: 5.849

6.  Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances.

Authors:  T C Wetter; C Trenkwalder; O Gershanik; B Högl
Journal:  Wien Klin Wochenschr       Date:  2001-04-17       Impact factor: 1.704

7.  Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study.

Authors:  C Monaca; A Duhamel; J M Jacquesson; C Ozsancak; A Destée; J D Guieu; L Defebvre; P Derambure
Journal:  Sleep Med       Date:  2006-06-05       Impact factor: 3.492

8.  Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

Authors:  Claudio Pacchetti; Raffaele Manni; Roberta Zangaglia; Francesca Mancini; Enrico Marchioni; Cristina Tassorelli; Michele Terzaghi; Maria Ossola; Emilia Martignoni; Arrigo Moglia; Giuseppe Nappi
Journal:  Mov Disord       Date:  2005-11       Impact factor: 10.338

9.  Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  J Neurosurg       Date:  2006-04       Impact factor: 5.115

10.  Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study.

Authors:  Gregory L Willis; E John D Turner
Journal:  Chronobiol Int       Date:  2007       Impact factor: 2.877

View more
  4 in total

1.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 2.  Biomarkers for Parkinson's Disease: Recent Advancement.

Authors:  Sharvari Lotankar; Kedar S Prabhavalkar; Lokesh K Bhatt
Journal:  Neurosci Bull       Date:  2017-09-21       Impact factor: 5.203

Review 3.  Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.

Authors:  Matteo Vismara; Beatrice Benatti; Gregorio Nicolini; Ilaria Cova; Edoardo Monfrini; Alessio Di Fonzo; Vincenza Fetoni; Caterina A Viganò; Alberto Priori; Bernardo Dell'Osso
Journal:  BMC Neurol       Date:  2022-05-05       Impact factor: 2.903

4.  Premotor biomarkers for Parkinson's disease - a promising direction of research.

Authors:  Brian R Haas; Tessandra H Stewart; Jing Zhang
Journal:  Transl Neurodegener       Date:  2012-05-31       Impact factor: 8.014

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.